TP53 and acute myeloid leukemia: Additionally, increased PRDX1 expression was correlated with TP53 mutations and was associated with worse clinical outcomes in AML patients (Fig. 3B, C), suggesting a potential role for PRDX1 in disease progression and treatment resistance.